Encouraging news for multidrug-resistant tuberculosis treatment

American Journal of Respiratory and Critical Care Medicine

Volumn 182, Issue 11, 2010, Pages 1337-1338

  Mitnick, Carole ^a   Horsburgh Jr , C Robert ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

CLINICAL TRIAL; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESISTANT TUBERCULOSIS; DRUG TOLERANCE; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RECURRENT DISEASE; STANDARDIZATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; INTERNATIONALITY; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 78649893121     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201007-1126ED     Document Type: Editorial

References (16)

1. Multidrug and extensively drug-resistant TB (M/XDR-TB). Global report of surveillance and response. 2010 [accessed 2010 July 9]. Available from: http://whqlibdoc.who.int/publications/2010/9789241599191-eng.pdf
2. Orenstein EW, Basu S, Shah S, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:153-161.
3. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-692.
4. Zaid RB, Nargis M, Neelotpol S. Acetylation phenotype status in a Bangladeshi population and its comparison with that of other Asian population data. Biopharm Drug Dispos 2004;25:237-241. (Pubitemid 39294801)
5. Rustomjee R, Leinhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, et al. A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-138. (Pubitemid 351212403)
6. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, et al. Substitution of moxifloxacin for isoniazid during the intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-280.
7. Conde MB, Efron A, Loredo C, De Souza GR, Gracxa NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009;373:1183-1189.
8. Burman WJ, Goldber S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, et al. Moxifloxacin versus ethambutol in the first 2 Months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-338.
9. Gumbo T, Louie A, Deziel M, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004;190:1642-1651.
10. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-1361.
11. Schaaf HS, Victor TC, Venter A, Brittle W, Jordaan AM, Hesseling AC, Marais BJ, van Helden PD, Donald PR. Ethionamide cross- and coresistance in children with isoniazid-resistant tuberculosis. Int J Tuberc Lung Dis 2009;13:1355-1359.
12. Katiyar SK, Bihari S, Prakesh S, Mamtani M, Kulkarni H. A randomized controlled trial of high-dose isoniazid adjuvant therapy for multidrugresistant tuberculosis. Int J Tuberc Lung Dis 2008;12:139-145. (Pubitemid 351212404)
13. Anonymous. Clofazimine. Tuberculosis (Edinb) 2008;88:96-99.
14. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Virú FA, Shin SS, Furin JJ, Becerra MC, Barry DJ, Kim JY, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004;363:474-481.
15. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, Sánchez E, Sarria M, Becerra M, Fawzi MC, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-128.
16. World Health Organization. WHO Leprosy Programme [accessed 2010 July 9]. Available from: http://www.who.int/lep/mdt/clofazimine/en/index.html